Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer

Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer

Abstract Cisplatin is a platinum-based first-line drug for treating ovarian cancer. However, chemotherapy tolerance has limited the efficacy of cisplatin for ovarian cancer patients. Research has demonstrated that cisplatin causes changes in cell survival and death signaling pathways through its int...

Full description

Bibliographic Details
Main Authors: Xiao-Yu Yan, Xian-Zhi Qu, Long Xu, Si-Hang Yu, Rui Tian, Xin-Ru Zhong, Lian-Kun Sun, Jing Su
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Cancer Cell International
Subjects:
p62
Cisplatin
Ovarian cancer
Drug resistance
Autophagy
Online Access:http://link.springer.com/article/10.1186/s12935-020-01196-w

Internet

http://link.springer.com/article/10.1186/s12935-020-01196-w

Similar Items